ClinicalTrials.gg
CompletedNCT00511602Updated Apr 30, 2012

Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes

A Phase 2 interventional study of Technosphere Insulin and Technosphere Placebo in Type 2 Diabetes Mellitus, sponsored by Mannkind Corporation. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-04-30.

Sponsored by Mannkind Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
26th of 49
123 · median 129
Started
2003
with 1 other
Phase 2
8 of 49
none open now
Registered
19th of 49
by date
Lead sponsor
13 of 49
Mannkind Corporation

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 26th largest by enrollment, is one of 2 that started in 2003, is one of 8 in phase 2, and was the 19th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

Primary objective to evaluate the effect of a 12-week treatment period with prandial administration of Technosphere Insulin on glucose control in subjects with T2 DM. Secondary objective is to Evaluate the safety and tolerability of a 12-week treatment period of Technosphere Insulin and Technosphere Placebo.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of T2 DM of >2 years and \<12 years duration
  • Insulin treatment naive treated with diet/exercise or single/combination oral anti-diabetic agents, such as metformin, sulfonylurea, and/or thiazolidinediones
  • Stable regimen for >3 months of oral anti-diabetes medication prior to enrollment
  • >6.6% and \<10.5%
  • \<38 kg/m2
  • 18-80 years of age
  • Baseline FVC and >80% and \<120% of predicted normal as measured by spirometry
  • Baseline DLCO >80% and \<120% of predicted normal

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of type 1 diabetes mellitus
  • Subjects currently using insulin therapy or at the time of screening
  • Known to the study drug or to drugs of similar chemical structures
  • Fasting plasma glucose >270 mg/dL without adequate explanation of a transient causality (screen could be repeated after a 2-week interim period)
  • History of severe or multiple allergies
  • History of tobacco or nicotine test at screening
  • Severe complications of diabetes including history of blindness from or Stage III or IV diabetic retinopathy, history of renal failure requiring dialysis or transplantation, history of amputation of limbs or digits related to diabetic vasculopathy
  • Treatment with another drug within 3 months prior to study entry (and for the duration of the study)
  • Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and inhaled , beta blockers, with the exception of beta blocker ophthalmic solutions for glaucoma or ocular hypertension, or hydrochlorothiazide (HCTZ) at doses >25 mg/day
  • Recent loss (within the 2 months prior to screening) of >5% of body weight
  • Evidence of moderate or greater ketones in urine or ketoacidosis at screening
  • History of or history of other known chronic pulmonary disease such as reactive airway disease, chronic bronchitis, emphysema, or asthma
  • Diagnosis of AIDS or ARC
  • A major psychiatric disorder that would have precluded satisfactory participation in this study
  • Subjects who had had a myocardial infarction or stroke within the preceding six months
  • Prior diagnosis of systemic or collagen vascular disease requiring heart disease graded as Class III or Class IV according to criteria
  • Prior treatment with, or participation in, a clinical study involving an inhaled insulin product
  • History of within 5 years of study entry (other than basal cell carcinoma)
  • Significant hepatic disease (as evidenced by or AST >3 times the reference normal range or >1.5 times the reference normal range)
  • Significant renal disease (as evidenced by creatinine >1.5 mg/dL for males or >1.3 mg/dL for females), proteinuria as evidenced by greater than "small" by dipstick measurement or >2 grams in 24 hours, dialysis, or history of renal transplant
  • History of previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Technosphere Insulin Inhalation Powder

    Drug: Technosphere Insulin

  • Placebo comparator
    Technosphere Inhalation Powder

    Drug: Technosphere Placebo

Interventions

  • Technosphere Insulin Inhalation Powder

  • DrugTechnosphere Placebo

    Technosphere Inhalation Powder

06

What researchers measure

Primary outcomes

  1. HbA1c change from baseline (week 2) to end of treatment (week 12)

    Time frame: 12 weeks

Secondary outcomes

  1. Area under the plasma glucose concentration versus time (AUCglucose)

    Timepoints: 0, 30, 60, and 120 minutes after TI administration

    Time frame: every 4 weeks

  2. Maximum glucose concentration (Cmax)

    Timepoints: 0, 30, 60, and 120 minutes after TI administration

    Time frame: every 4 weeks

  3. Time to maximum glucose concentration (tmax)

    Timepoints: 0, 30, 60, and 120 minutes after TI administration

    Time frame: every 4 weeks

  4. Area under the plasma glucose concentration versus time (AUCglucose)

    Timepoints: 0, 30, 60, and 120 minutes after Technosphere Placebo administration

    Time frame: every 4 weeks

  5. Maximum glucose concentration (Cmax)

    Timepoints: 0, 30, 60, and 120 minutes after Technosphere Placebo administration

    Time frame: every 4 weeks

  6. Time to maximum glucose concentration (tmax)

    Timepoints: 0, 30, 60, and 120 minutes after Technosphere Placebo administration

    Time frame: every 4 weeks

  7. Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations

    Time frame: every 2 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Rosenstock J, Bergenstal R, Defronzo RA, Hirsch IB, Klonoff D, Boss AH, Kramer D, Petrucci R, Yu W, Levy B; 0008 Study Group. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008 Nov;31(11):2177-82. doi: 10.2337/dc08-0315. Epub 2008 Aug 4. PubMed 18678610 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Nov 2004 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2007
First posted
Aug 6, 2007
Start
Dec 2003
Primary completionActual
Nov 2004
CompletionActual
Dec 2005
Last update
Apr 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00511602
Responsible party
Sponsor
First posted
Aug 6, 2007
Start date
Dec 2003
Primary completion
Nov 2004
Completion
Dec 2005
Last update
Apr 30, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion